<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144731">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059785</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-HA1301</org_study_id>
    <nct_id>NCT02059785</nct_id>
  </id_info>
  <brief_title>Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke</brief_title>
  <official_title>Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke---Randomized, Double-blind, Placebo-controlled, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is a Randomized, double-blind, placebo-controlled, multicenter clinical study.
      Chinese subjects with Ischemic Stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will randomly enter into one of two groups,the period of treatment is 14
      days,follow-up to the 90th days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determination the proportion of subjects that 0-1 score of mRS after treatment 90 days</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare treatment arms in terms of change from baseline to endpoint in NIHSS score.</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Pinocembrin for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pinocembrin for Injection</intervention_name>
    <arm_group_label>Pinocembrin for Injection</arm_group_label>
    <other_name>DL0108</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be 35-75years old(hospital patients) ,both male and female; Patients
             had a clinical diagnosis of acute stroke that had commenced within the six hours
             before entry into the study; Patients had a score of 6-20 on the National Institutes
             of Health Stroke Scale and the score ≥2 of item 5 and/or 6; For the first time or
             always without obvious sequelae of stroke disease(mRS≤1）

        Exclusion Criteria:

          -  The disease such as Acute intracerebral hemorrhage,tumor and encephalitis ;cause
             which cause  similar symptoms; TIA; Pregnancy and breast-feeding women and male
             subjects with fertility program
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Yong Jun, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tiantan Hospital affilliated to Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Ji Ling, Master</last_name>
    <phone>86-311-67808812</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital affilliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Yong Jun, Ph.D</last_name>
      <phone>86-01-67096611</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pinocembrin for Injection</keyword>
  <keyword>Placebo</keyword>
  <keyword>mRS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
